/DMYD-B.ST
DMYD-B.ST Stock - Diamyd Medical AB (publ)
Healthcare|BiotechnologySTO
$10.08+2.23%
+$0.22 (+2.23%) • Dec 23
57
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.52
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.50
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $11.09
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DMYD-B.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$9.98 – $10.18
TARGET (TP)$11.59
STOP LOSS$9.27
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.76
52W High$19.50
52W Low$7.50
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $130,000 | $130,000 | $546,000 | $454,000 | $253,000 |
| Gross Profit | $-3,705,000 | $-3,580,000 | $-3,088,000 | $-3,949,000 | $-2,248,000 |
| Gross Margin | -2850.0% | -2753.8% | -565.6% | -869.8% | -888.5% |
| Operating Income | $-183,236,000 | $-146,567,000 | $-120,806,000 | $-118,176,000 | $-85,880,000 |
| Net Income | $-169,777,000 | $-151,850,000 | $-116,073,000 | $-103,517,000 | $60.05M |
| Net Margin | -130597.7% | -116807.7% | -21258.8% | -22801.1% | 23733.6% |
| EPS | $-1.51 | $-1.60 | $-1.48 | $-1.36 | $0.87 |
Company Overview
Diamyd Medical AB (publ) develops therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy diabetes vaccine, which is in phase IIb clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes; and Remygen, an oral regenerative and immunomodulatory drug candidate, which is in phase I/II clinical trial for the treatment of autoimmune and type 2 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was incorporated in 1984 and is based in Stockholm, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
DMYD-B.STBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.41
Q2 2025
EPS Surprise History
Q4 23
No data
Q1 24
No data
Q1 24
No data
Q2 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q2 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | Jun 25, 2025 | — | $-0.41 | — | — |
Q2 2025 | Apr 9, 2025 | — | $-0.43 | — | — |
Q1 2025 | Jan 29, 2025 | — | $-0.35 | — | — |
Q4 2024 | Oct 9, 2024 | — | $-0.50 | — | — |
Q2 2024 | Jun 26, 2024 | — | $-0.41 | — | — |
Q1 2024 | Mar 27, 2024 | — | $-0.31 | — | — |
Q1 2024 | Jan 24, 2024 | — | $-0.37 | — | — |
Q4 2023 | Oct 11, 2023 | — | $-0.46 | — | — |
Q2 2023 | Jun 28, 2023 | — | $-0.27 | — | — |
Q2 2023 | Apr 5, 2023 | — | $-0.32 | — | — |
Q1 2023 | Jan 25, 2023 | — | $-0.42 | — | — |
Q4 2022 | Oct 5, 2022 | — | $-0.51 | — | — |
Q2 2022 | Jun 22, 2022 | — | $-0.22 | — | — |
Q1 2022 | Mar 30, 2022 | — | $-0.12 | — | — |
Q1 2022 | Jan 26, 2022 | — | $-0.52 | — | — |
Q4 2021 | Oct 13, 2021 | — | $-0.39 | — | — |
Q2 2021 | Jun 23, 2021 | — | $-0.46 | — | — |
Q1 2021 | Mar 26, 2021 | — | $0.21 | — | — |
Q1 2021 | Jan 20, 2021 | — | $1.48 | — | — |
Q4 2020 | Oct 7, 2020 | — | $-0.19 | — | — |
Latest News
Loading news...
Frequently Asked Questions about DMYD-B.ST
What is DMYD-B.ST's current stock price?
Diamyd Medical AB (publ) (DMYD-B.ST) is currently trading at $10.08 per share. The stock has moved +2.23% today.
What is the analyst price target for DMYD-B.ST?
No analyst price targets are currently available for this stock.
What sector is Diamyd Medical AB (publ) in?
Diamyd Medical AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is DMYD-B.ST's market cap?
Diamyd Medical AB (publ) has a market capitalization of $1.35 billion, making it a small-cap company.
Does DMYD-B.ST pay dividends?
No, Diamyd Medical AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBICO.ST
BICO Group AB (publ)
$19.00
Mkt Cap: $1.3B
BINV.ST
BioInvent International AB (publ)
$29.75
Mkt Cap: $2.0B
CANTA.ST
Cantargia AB (publ)
$4.09
Mkt Cap: $1.0B
EGTX.ST
Egetis Therapeutics AB (publ)
$5.30
Mkt Cap: $1.9B
GENO.ST
Genovis AB (publ.)
$21.20
Mkt Cap: $1.4B
IBT-B.ST
Infant Bacterial Therapeutics AB (publ)
$49.00
Mkt Cap: $0.6B
ONCO.ST
Oncopeptides AB (publ)
$4.57
Mkt Cap: $1.0B
OSSD.ST
OssDsign AB (publ)
$11.46
Mkt Cap: $1.3B
SYNACT.ST
SynAct Pharma AB
$23.80
Mkt Cap: $1.3B
XSPRAY.ST
Xspray Pharma AB (publ)
$31.20
Mkt Cap: $1.1B
Explore stocks similar to DMYD-B.ST for comparison